J. Goldman & Co’s Akero Therapeutics AKRO Stock Holding History

J. Goldman & Co’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-27,000	Closed	-$1.37M	–	331
2023 Q3	$1.37M	Buy	+27,000	New	+$1.26M	0.05%	223
2023 Q1	–	Sell	-13,600	Closed	-$745K	–	350
2022 Q4	$745K	Buy	+13,600	New	+$583K	0.04%	244

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

J. Goldman & Co's AKRO Position: Q3 2025 in Review

J. Goldman & Co sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 65,628 shares — an estimated $3.18M sold.

J. Goldman & Co first reported a position in AKRO in Q1 2025 and held it in 2 quarters. The position peaked at $3.5M in Q2 2025. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

J. Goldman & Co reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
J. Goldman & Co sold 65,628 Akero Therapeutics shares in Q3 2025, an estimated $3.18M.
J. Goldman & Co first reported a position in Akero Therapeutics in Q1 2025 and held it in 2 quarters.
J. Goldman & Co's Akero Therapeutics position peaked at $3.5M in Q2 2025.
265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.